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Positive or Negative MARE-Dependent
Transcriptional Regulation Is Determined
by the Abundance of Small Maf Proteins
structure, which mediates DNA binding and dimerization
activities.
Over the past five years, the number of vertebrate
transcription factors that can bind specifically to MAREs
has increased exponentially. We previously showed
Hozumi Motohashi,*† Fumiki Katsuoka,*
Jordan A. Shavit,† James Douglas Engel,†
and Masayuki Yamamoto*‡
*Center for Tsukuba Advanced Research Alliance
and Institute of Basic Medical Sciences
that, besides MafK, MafF and MafG can also serve asUniversity of Tsukuba
partners for CNC family proteins (Fujiwara et al. 1993;1-1-1 Tennoudai
Kataoka et al. 1995). Additionally, five CNC family mem-Tsukuba 305-8577
bers (called Nrf1, Nrf2, Nrf3, Bach1, and Bach2) can alsoJapan
dimerize with small Maf proteins (Chan et al. 1993; Moi†Department of Biochemistry, Molecular Biology,
et al. 1994; Itoh et al. 1995; Oyake et al. 1996; Kobayashiand Cell Biology
et al. 1999). Furthermore, since all MARE consensusNorthwestern University
sites have a canonical AP1 motif embedded within,Evanston, Illinois 60208
some Jun and Fos family factors can also heterodimer-
ize with Maf/CNC proteins. Finally, three large Maf fac-
tors are also capable of binding to the MARE elementSummary
(Kataoka et al. 1993; Kataoka et al. 1994a). The vast
number of possible homo- and heterodimeric factorThe small Maf transcription factor proteins bind to
combinations which can bind to MARE elements thusMaf Recognition Elements (MAREs) by dimerizing with
have the potential to elicit transcriptional responsesCNC proteins or themselves. We undertook experi-
ranging from subtle to robust from a single MARE sitements to clarify the functional relationship between
(Motohashi et al. 1997).the small Mafs and their partners in vivo. Embryos
The small Mafs were originally reported to be ubiqui-expressing abundant transgene-derived MafK died of
tous proteins (Andrews et al. 1993b; Fujiwara et al. 1993),severe anemia, while lines expressing lower levels of
while its CNC partner molecule, p45, was shown to besmall Maf lived to adulthood. Megakaryocytes from
a lineage-restricted factor (Andrews et al. 1993a). Thesethe latter overexpressing lines exhibited reduced pro-
preliminary characterizations inadvertently promotedplatelet formation and MARE-dependent transcription,
the concept that the activity of CNC factors, rather thanphenocopying mafG null mutant mice. When the mafG
the “ubiquitous” small Maf proteins, was the major de-null mutants were bred to small Maf-overexpressing
terminant of transcriptional regulation through MAREtransgenic animals, both loss- and gain-of-function
sequences. However, subsequent lines of evidence im-phenotypes were reversed. These results provide di-
plicated the small Maf genes in strict tissue-specificrect in vivo evidence that transcriptional regulation
control (Igarashi et al. 1995a; Motohashi et al. 1996;through MARE elements hinges on an exquisitely sen-
Motohashi et al. 1998; Katsuoka et al. 2000). Examina-sitive balance of activating CNC molecules and their
tion of LacZ expression from the gene targeted allelessmall Maf partners.
of heterozygous mafF, mafG, and mafK mutants conclu-
sively demonstrated that the expression profile of eachIntroduction
small Maf is unique (Shavit et al. 1998; Onodera et al.
1999). Thus, the expression of the small Maf factors is,The Maf recognition element (MARE; aka NF-E2 binding
like many of their CNC partners, under strict spatial and
site) is a central cis contributor to the transcription of
temporal regulation during embryonic development.
many genes expressed in erythroid and megakaryocytic
One early speculation suggested that the small Maf
cells. MAREs have been identified in the locus control factors might be able to function as both positive and
region of mammalian b-globin loci (Andrews et al. 1993a) negative regulators within this plausibly extensive bZip
and in the proximal promoters of the genes encoding transcription factor network (Engel 1994). Since the
erythroid 5-aminolevulinate synthase (ALAS-E; Cox et small Maf proteins lack any canonical activation domain,
al. 1991) and porphobilinogen deaminase (PBGD; Mig- homodimers could negatively regulate MARE-depen-
notte et al. 1989). A MARE-specific binding activity was dent transcription either actively (as transcriptional re-
first identified as NF-E2, a heterodimeric protein com- pressors) or passively (by competitively inhibiting acti-
plex whose subunits consisted of p45 and p18 or MafK vator binding; Igarashi et al., 1994). These studies all
(Andrews et al. 1993a, 1993b; Igarashi et al. 1994). MafK suggested that maintaining an optimal quantitative bal-
shares the strongest homology with a family of factors ance between small Maf and CNC proteins might be
related to the c-Maf proto-oncogene (Nishizawa et al. vital for promoting maximal MARE-dependent transcrip-
1989), while the p45 subunit is most closely related to tional activation.
the Drosophila nuclear regulatory Cap-N-Collar (CNC) One important insight from the cell culture studies
protein (Mohler et al. 1991). Both CNC and small Maf was that modest variation in small Maf concentrations
proteins possess a basic region/leucine zipper (bZip) might be sufficient to effect the positive to negative
signal transduced through a MARE element (Nagai et
al., 1998). However, these inferences were muted by the‡ To whom correspondence should be addressed (e-mail: masi@
tara.tsukuba.ac.jp). fact that it was not possible at that time to accurately
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Figure 1. Anemic Founder Embryos Bearing a GATA-1-directed MafK Transgene
F0 analysis of fertile oocyte injection of G1-HRD-MafK. (A and B) Representative transgenic embryos at E10.5 (TG1) are depicted alongside
transgene-negative littermates (WT). (C–F) Histological examination of E10.5 F0 embryos. An embryo bearing the G1-HRD-MafK transgene (C
and E; TG1) and a wild-type littermate (D and F; WT) were sectioned. (C) and (D) are cross sections stained with hematoxylin and eosin. (E)
and (F) were immunostained with anti-hemoglobin antibody (light brown) and then counterstained with methyl green. Abbreviations: a, aorta;
h, heart; v, cardinal vein. Scale bar corresponds to 210 mm (C and D) or 175 mm (E and F). (G) Gene expression in E9.5 F0 yolk sacs. RNA
was extracted from whole yolk sacs, and semiquantitative RT-PCR was performed. Lanes 1 and 2 are samples from pale, small, very anemic
transgenic embryos, whereas lane 3 was an only slightly anemic founder. Lanes 4 and 5 are wild-type control littermates. Lane 6 is water.
assess the overall dynamics of these interactions in vivo. We found that founder transgenic embryos express-
ing high levels of MafK died of severe anemia. In con-In particular, the significance of possible antagonistic
(positive or negative) regulation by the small Maf factors trast, mice producing lower amounts of MafK or MafG
completed gestation, thus allowing us to establish smallalone had not been established. We therefore set out to
examine the physiological consequences of modulating Maf-expressing transgenic lines. While erythropoiesis
was normal in these (gain-of-function) lines, their mega-small Maf concentrations in vivo to test for hypothetical
bidirectional control by these proteins within the context karyocytes displayed reduced proplatelet formation
(PPF) and reduced megakaryocytic MARE-dependentof the entire repertoire of other bZip transcription factors
(e.g., small and large Mafs, CNC proteins, and Jun/Fos gene expression, phenotypes remarkably similar to
those observed in mafG germ line mutant mice. Whenfamily members) that might be present in a normal cellu-
lar milieu. we intercrossed the mafG null mutants with the GATA-
1-directed MafK or MafG transgenics, we found that theIn order to examine the effect of small Maf overexpres-
sion on a single MARE-dependent process, we gener- megakaryocytic phenotype was rescued in compound
mutants. These experiments directly demonstrate thatated transgenic mice bearing either a MafK or MafG
cDNA directed by a GATA-1 gene regulatory cassette, the MARE constitutes a sensitive genetic switch that
mediates repression or activation as a consequence ofsince the MARE is known to act as a critical cis element
for gene regulation in both erythroid and megakaryo- the quantitative balance between small Maf transcrip-
tion factors and their partners.cytic cells. We previously showed that three separate
segments of the GATA-1 gene (including an erythroid
promoter, a 59 distal element, and an element in the Results
first intron) together comprise the sequences that are
necessary and sufficient for exerting full GATA-1 tran- Myeloid-Specific MafK Overexpression in Founders
Causes Lethal Embryonic Anemiascriptional control in erythroid as well as megakaryo-
cytic lineages (Onodera et al., 1997). We thus hoped to To analyze the effects of modulating MafK abundance
on megakaryopoiesis and erythropoiesis, we generateddetermine the effects of small Maf gain-of-function in
vivo after restricting its expression to a specific subset transgenic mice bearing a MafK cDNA placed under the
control of the GATA-1 locus hematopoietic regulatoryof well characterized myeloerythroid lineage cells.
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Figure 2. The MafK Zipper Mutant L2PM4P
Does Not Bind MARE DNA nor Affect Tran-
scription
(A) DNA binding properties of MafK and MafK
L2PM4P were examined by EGMSA. MafK
and MafK L2PM4P were in vitro translated
and then incubated with a 32P-labeled oligo-
nucleotide containing the MARE (NF-E2) con-
sensus sequence (lanes 2 and 4). NF-E2 p45
was added to the reaction to examine its abil-
ity to heterodimerize (lanes 6 and 8). An arrow
and an arrowhead indicate the positions of
shifted bands composed of MafK homodi-
mers or of MafK/p45 NF-E2 heterodimers, re-
spectively. The bands were specifically com-
peted by the addition of a 400-fold molar
excess of unlabeled oligonucleotide (lanes 3
and 7). Wheat germ extract (WG) without tem-
plate DNA was a negative control (lane 5).
(B) Transfection was performed in NIH3T3
cells. Relative luciferase activity is shown,
and luciferase activity without addition of ef-
fector plasmids was arbitrarily set at 100%.
The amount of transfected effector plasmids, pIM-MafK and pIM-MafK L2PM4P, is shown at the bottom. This represents the average of three
independent experiments, and error bars indicate the standard deviation between experiments.
(C) Immunoblot analysis of nuclear extracts prepared from transfected NIH3T3 cells. NIH3T3 cells were transfected with pIM-MafK, pIM-MafK
L2PM4P, or vector. Ten micrograms of each nuclear extract was applied per lane; MafK was detected by reaction with anti-p18 (MafK)
antibody. Molecular size markers are on the right.
domain (G1-HRD) that restricts transgene expression to entiation process per se was less severely affected by
erythroid cells and megakaryocytes (Experimental Pro- an excess of transgene-derived MafK. As expected from
cedures; Onodera et al. 1997). Since the G1-HRD is the decrease in blood cell number, the mRNA level
first activated in hematopoietic cells of the yolk sac, we of MARE-dependent erythroid genes (e.g., ey-globin,
examined primitive erythropoiesis in founder transgenic ALAS-E, and PBGD) was diminished in whole yolk sacs
embryos (F0 assay). of the transgenic embryos (data not shown).
Transgenic founders recovered at gestational days Since some transgenic embryos did not appear to be
10.5 and 11.5 (E10.5 and E11.5) were examined macro- anemic, we speculated that the expression level of the
scopically for anemia. We found that four of twenty- MafK transgene among individual embryos might be
six (15.4%) E10.5 and three out of eight (37.5%) E11.5 variable as a consequence of integration position or
transgene-positive embryos appeared very anemic in transgene copy number, hence the observed variability
comparison to their nontransgenic littermates. Two rep- in phenotype. To test whether there was a correlation
resentative anemic transgenic E10.5 embryos with lit- between MafK expression level and the severity of ane-
termate controls are shown in Figures 1A and 1B. Trans- mia, we quantified transgene-derived MafK mRNA (Fig-
genic yolk sacs and embryos were very pale in color ure 1G, G1-HRD-MafK) and total MafK mRNA (Figure
(Figures 1A and 1B, left) when compared to the bright 1G, MafK) expressed in transgenic yolk sacs by RT-
red vasculature in nontransgenic littermates (Figures 1A PCR. MafK mRNA levels were almost normal, or even
and 1B, right). The anemic transgenic embryos were
slightly reduced, in the severely anemic embryos (Figure
also smaller than their nontransgenic littermates. Since
1G, lanes 1 and 2) in comparison to the transgenics
MafK was placed under the transcriptional control of
that displayed little anemia (lane 3) or to nontransgenicGATA-1, it would be expressed specifically in primitive
littermates (lanes 4 and 5). These results, however, mustred blood cells prior to E10.5 (Onodera et al., 1997). The
be interpreted in light of the conspicuous diminution inobserved embryonic anemia was the first detectable
blood cell number in the severely anemic embryos (seedirect effect of MafK overexpression, subsequently
Figures 1C and 1D). When normalized to erythroid cell-leading to secondary growth retardation and embryonic
specific GATA-1 mRNA, the data indicate that total MafKdemise.
(both endogenous and transgene-derived) mRNA wasWe next performed histological analysis of the trans-
expressed approximately 16- to 24-fold more abun-genic embryos. Three F0 embryos at E10.5 were sec-
dantly in the blood of transgenic embryos with pro-tioned and stained with hematoxyline and eosin, and 10
nounced anemia (Figure 1G, lanes 1 and 2) or 1.6-foldseparate sections were examined in detail. As expected,
higher in those displaying no anemia (lane 3). Thus, thethe number of circulating blood cells was significantly
level of transgene-derived MafK mRNA correlatesfewer in the heart cavity and major vasculature of trans-
strongly with the severity of anemia. This result suggestsgenic embryos (Figures 1C and 1D). Despite the scarcity
that robust expression of the MafK transgene leads toof red blood cells, they were hemoglobinized in the ane-
embryonic lethality by disrupting primitive erythropoie-mic transgenic embryos (Figures 1E and 1F). This obser-
sis, while modestly elevated levels of MafK do not inter-vation suggested that the proliferation of erythroid
progenitors might be compromised, but that the differ- fere with embryogenesis.
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Table 1. Macroscopic Observation of MafK F0 (Founder) Transgenic Embryos
A. Hematopoietic Index of Embryos Score (0–6) 5 Y 1 H 1 A
Yolk sac score (Y) Heart Score (H) Aortic score (A)
2 Blood vessels filled with red blood cells to 2 Heart filled with red blood 2 Full length of aorta filled with
periphery cell red blood cells
1 Red blood cells observed only in large 1 Few red blood cells in the 1 Part of aorta filled with red
vessels heart blood cells
0 No red blood cell mass observed in any 0 No red blood cells in the 0 No red blood cell observed in
vessels heart aorta
B. Hematopoietic Scores in MafK or MafK L2PM4P Transgenic Embryos and Controls
score
0 1 2 3 4 5 6 total
G1-HRD-MafK transgenic
E9.5 2 0 0 2 0 0 2 6
E10.5 3 4 4 6 0 1 28 46
E11.5 3 1 0 2 0 0 5 11
total 8 5 4 10 0 1 35 63
nontransgenic
E9.5 0 0 0 1 0 0 2 3
E10.5 0 1 1 2 6 1 37 48
E11.5 0 0 0 2 0 0 22 24
total 0 1 1 5 6 1 61 75
G1-HRD-MafK L2PM4P transgenic
E9.5 0 0 0 1 0 0 6 7
E10.5 0 0 0 0 2 1 7 10
E11.5 0 0 0 0 0 1 9 10
total 0 0 0 1 2 2 22 27
nontransgenic
E9.5 0 0 0 1 1 1 13 16
E10.5 0 0 0 0 2 0 14 16
E11.5 0 0 0 0 1 0 7 8
total 0 0 0 1 4 1 34 40
MafK Transgenic Perturbation of Primitive (E11.5) transgenic embryos, and 0/3 (E9.5), 2/48 (E10.5),
or 0/24 (E11.5) nontransgenic embryos. The number ofErythropoiesis Is Dependent on Small
Maf Dimerization transgenic anemic embryos was significantly greater (17
out of 63 embryos) than in the nontransgenic group (2To determine whether transgene-induced anemia was
a direct consequence of MafK function, we employed out of 75 embryos), and this difference was statistically
significant (p , 0.001 by x2 test).a MafK mutant (L2PM4P; Kataoka et al., 1995) that has
two amino acid substitutions which impair its dimeriza- When MafK L2PM4P cDNA was substituted for wild-
type MafK in the G1-HRD cassette, embryos with scorestion, and therefore DNA binding, activity as reflected in
electrophoretic gel mobility shift assays (EGMSA, Figure less than 3 were observed in 0/7 (E9.5), 0/10 (E10.5), or
0/10 (E11.5) transgenics compared to 0/16 (E9.5), 0/162A). Unlike wild-type MafK, the mutant was incapable
of repressing MARE-dependent transcription in cotrans- (E10.5), or 0/8 (E11.5) nontransgenic embryos. The total
number of anemic embryos was 0/27 for the transgenicfection assays (Figure 2B), despite accumulating com-
parable amounts of protein in transfected cells (Figure L2PM4P mutant MafK group and 0/40 in the nontrans-
genic littermate cohort. In summary, MafK overexpres-2C). These results showed that the MafK mutant
L2PM4P is an inconsequential transcriptional regulator sion in primitive erythroid cells results in high incidence
of anemia, while MafK L2PM4P expression does not,in transfected tissue culture cells.
We next generated transgenic mice bearing the MafK and the adverse effect of MafK overexpression on primi-
tive erythropoiesis is due, at least in part, to its abilityL2PM4P mutant cDNA driven by the G1-HRD, and com-
pared the phenotype of these transgenic animals to to dimerize and/or to bind DNA. Therefore, we conclude
that excess transgene-derived MafK acts directly onthose generated using wild-type MafK cDNA. To quan-
tify the comparison, we established criteria for evaluat- MARE sites in vivo to negatively regulate primitive eryth-
ropoiesis.ing anemic severity where the number of red blood cells
in the yolk sac vasculature, embryonic heart cavity, and
aortic cavity were independently assigned numerical Surplus Small Maf Inhibits Proplatelet Formation
in Megakaryocytesvalues from 0 to 2. The mean hematopoietic score is
then the sum of the three independent scores (Table While excessive MafK expression in embryos led to ane-
mic death, some transgenic embryos were able to es-1A). F0 embryos were first scored macroscopically and
then genotyped by PCR (Table 1B). When transgenic cape lethality, presumably because the transgene was
expressed at sublethal dosages. We were therefore ableembryos injected with wild-type MafK cDNA were exam-
ined, scores of less than 3 (i.e., relatively severe anemia) to establish transgenic lines to examine the effect of (in
most cases, slight) MafK overexpression on definitivewere recorded for 2/6 (E9.5), 11/46 (E10.5), or 4/11
A MARE-Dependent Genetic Switch
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Table 2. PPF Incidence in Megakaryocytes from Transgenic Animals Expressing Different Levels of Small Maf Proteins
A. PPF Incidence in TgMafK/GFP, TgMafG/GFP and mafG-null Mutant Mice
Transgenic genotype PPF frequency (%)
GFP TgGFP28 45.6 6 2.3
Mafk TgMafK548 5.9 6 3.2
TgMafK549 9.2 6 6.1
TgMafK686 4.3 6 1.1
TgMafK690 6.5 6 2.2
TgMafK802 7.1 6 1.0
MafG TgMafG825 5.6 6 3.1
TgMafG705 37.8 6 12.2
— WT 27.7 6 16.7
mafG2/2 0.98 6 0.51
B. PPF Incidence in mafG2/2::TgMafK/GFP or mafG2/2::TgMafG/GFP Compound Mutant Mice
Transgenic line genotype PPF frequency (%)
548 (MafK high producer) mafG2/2 0.54 6 0.34
mafG2/2::TgMafK548 13.5 6 1.9
TgMafK548 5.3 6 2.1
686 (MafK high producer) mafG2/2 0.046 6 0.08
mafG2/2::TgMafK686 9.1 6 1.5
TgMafK686 4.6 6 0.91
549 (MafK low producer) mafG2/2 0.21 6 0.13
mafG2/2::TgMafK549 4.9 6 1.5
TgMafK549 8.5 6 2.9
825 (MafG high producer) mafG2/2 0.1 6 0.03
mafG2/2::TgMafG825 30.0 6 1.1
TgMafG825 7.3 6 0.9
705 (MafG low producer) mafG2/2 0.03 6 0.06
mafG2/2::TgMafG705 5.5 6 1.0
TgMafG705 34.2 6 15.4
hematopoiesis. In generating these lines, a second con- MARE-dependent transcription as critical for mega-
karyocyte differentiation (Shivdasani et al. 1995; Shavitstruct in which GFP was directed by the G1-HRD reg-
ulatory cassette was coinjected with G1-HRD-MafK. et al. 1998). In particular, proplatelet formation (PPF) is
markedly reduced in megakaryocytes of both mafG nullCointegration of the two plasmids would then lead to
identification of MafK-overexpressing cells as those that and p45 null mutants (Lecine et al. 1998a; Onodera et
al. 2000). We therefore determined whether or not MafKwere readily detected by green fluorescence. Five inde-
pendent lines bearing G1-HRD-MafK/GFP and three in- overexpression would affect PPF.
Proplatelets are arrays of beaded filamentous cell pro-dependent lines harboring G1-HRD-GFP alone (for
MafK-less controls) were recovered. As anticipated, the jections, and PPF is thought to be a major pathway
leading to platelet production (Choi et al. 1995; Italianocoinjected MafK and GFP transgenes integrated into
the same chromosomal locus, since the two activities et al. 1999). When isolated from bone marrow, usually
20%–40% of megakaryocytes generate proplateletscosegregated in subsequent progeny. The copy number
of the G1-HRD-MafK transgenes was determined by after one to two days in culture. We calculated the PPF
incidence in each MafK transgenic line by counting GFP-quantitative PCR (TaqmanTM PCR) in each line, and
ranged from 2 to 10 transgene copies (data not shown). positive megakaryocytes (Table 2A). Nearly 46% of GFP-
positive megakaryocytes from a TgGFP line showed nor-To compare the endogenous and transgene-derived
protein levels, we examined MafK abundance in bone mal PPF (Figures 3B and 3C). In contrast, most of the
GFP-positive megakaryocytes from the TgMafK/GFP coin-marrow cells by immunoblotting with an anti-p18 (MafK)
antibody which reacts with MafK but not with MafG. jected lines did not form proplatelets (Figures 3D and
3E). Megakaryocytes from the high MafK producersIn four transgenic lines (TgMafK548, TgMafK686, TgMafK690, and
TgMafK802), MafK levels were elevated more than 5-fold (lines 548, 686, 690, and 802) had significantly lower
PPF incidence, while megakaryocytes from the lowestin comparison to endogenous MafK in nontransgenic
littermates or in mice bearing GFP alone (Figure 3A and MafK producer (549) displayed only mild PPF inhibition
(Table 2A). Thus, we concluded that excessive MafKdata not shown), while TgMafK549 was a relatively lower
level expressing line. When definitive erythropoiesis in blocked PPF in megakaryocytes, and that the extent of
PPF inhibition correlated with MafK expression levelsthese lines was examined further, no sign of anemia
was evident (data not shown). in the hematopoietic compartment.
To test the hypothesis that elevated small Maf activityMegakaryopoiesis is another hematopoietic compart-
ment in which the G1-HRD cassette shows strong tran- in megakaryocytes was directly affecting PPF, we exam-
ined MARE binding activity in megakaryocytes isolatedscriptional activity (Onodera et al. 1997). Germ line
mutations in both the p45 and mafG genes implicated from animals of various genotypes. In wild-type mega-
Cell
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Figure 3. Small Maf Transgenic Mice Display Altered MARE Binding Activity and Inhibited Proplatelet Formation in Megakaryocytes
(A) MafK expression levels were analyzed in nuclear extracts recovered from total bone marrow cells of adult transgenic mice by immunoblotting
using the anti-p18 (MafK) antibody. Line 28 bears G1-HRD-GFP, while the others coincorporated G1-HRD-MafK into the germ line.
(B–E) Proplatelet formation was analyzed in bone marrow megakaryocytes of transgenic mice. Cultured megakaryocytes from TgGFP28 (B and
C) and TgMafK548 (D and E) are shown. Acetylcholinesterase activity stained dark brown (B and D). GFP-positive megakaryocytes (C and E) and
proplatelet filaments (C) were observed by fluorescence microscopy.
(F) MARE binding activity in megakaryocytes isolated from MafK transgenic mice. 1.5 mg of nuclear extract from WT (lanes 1–4), TgMafK686 (lanes
5–8), or TgMafK548 (lanes 9–13) was incubated with a 32P-labeled oligonucleotide containing the NF-E2/MARE consensus sequence. The array
of complexes formed (in the absence of antisera) are indicated by an arrow. WG, wheat germ extract.
(G) Total small Maf expression levels in adult transgenic bone marrow were determined using anti-small Maf antiserum (Experimental Proce-
dures). All lines shown bear G1-HRD-MafG/GFP transgenes.
karyocytes, the major MARE binding activity was p45/ ties (if any) in an in vivo situation that was sensitive to
variations in small Maf concentration, and thus perhapssmall Maf heterodimers, which react with an anti-small
Maf antiserum (that recognizes both MafK and MafG) as in the regulation of PPF. To this end, four independent
MafG-overexpressing transgenic lines were generatedwell as with anti-p45 (Figure 3F, lanes 1–4). In contrast,
megakaryocytes recovered from MafK transgenics dis- by coinjecting G1-HRD-MafG and G1-HRD-GFP into fer-
tilized eggs. The expression levels in each line wereplayed an intense binding activity which was ablated
by inclusion of the anti-small Maf antibody, but was examined by immunoblotting with the anti-small Maf
antiserum (Figure 3G). TgMafG825 was the highest MafGunaffected by addition of anti-p45 (Figure 3F, lanes 5–8).
Thus, the higher mobility complex did not contain p45, producer, while others (lines 705, 708, and 675) were
low producers. When PPF in these independent linesas the intensity of the supershifted band remained con-
stant upon addition of excess anti-p45 (Figure 3F, lanes was examined, TgMafG825 displayed prominent inhibition,
while line TgMafG705, a low producer, showed none (Table11 and 12). Furthermore, the high mobility protein:DNA
complex comigrated with in vitro translated MafK (Fig- 2A). Once again, the extent of PPF inhibition paralleled
small Maf (in this case, MafG) expression level. Thus,ure 3F, lanes 14). Therefore, these rapidly migrating spe-
cies of MARE binding complexes in MafK-overexpress- these experiments did not reveal differences between
MafK and MafG (see below).ing megakaryocytes consisted principally of small Maf
dimers, but did not include p45. These results show that
small Maf overexpression leads to a qualitative alteration Myeloid-Specific Expression of Small Maf Proteins
Restores Proplatelet Formation in mafGin MARE binding activity in megakaryocytes in vivo.
One of the original goals of this study was to determine Null Mutant Mice
We recently showed that PPF is markedly impaired inwhether MafK and MafG displayed any functional dif-
ferences in vivo. Although no biochemical differences mafG null mutant mice (Onodera et al. 2000). Practically
no PPF was observed in mafG null mutant megakaryo-between them had been documented in vitro or in
transfecto, we hoped to be able to detect such dispari- cytes under culture conditions where wild-type mice
A MARE-Dependent Genetic Switch
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displayed normal (20%–40%) PPF incidence (Figures
4B and 4C; Table 2A). Considered in the context of the
present experiments, the observation that excess MafK
or MafG also leads to PPF inhibition was intriguing.
Since MafG is the major small Maf protein expressed in
adult megakaryocytes (Shavit et al. 1998; Lecine et al.
1998b), there is a dearth of overall small Maf activity in
mafG null megakaryocytes, and thus PPF is defective in
their absence. In contrast, megakaryocytes expressing
MafK or MafG transgenes have a surfeit of small Mafs.
Thus, either under- or over-abundance of small Maf pro-
teins in megakaryocytes disrupts PPF.
To test whether perturbation of the balance between
the small Mafs and their activating CNC partners affect
transcription through MAREs in vivo, we varied the con-
centration of small Maf proteins in megakaryocytes by
crossing mafG germ line mutant mice with various G1-
HRD-MafK/GFP or -MafG/GFP lines. Any phenotype due
to loss of mafG should be abrogated by excess small
Maf derived from the transgene. Reciprocally, any phe-
notype due to excess transgene-derived MafK or MafG
should be remedied by the mafG loss-of-function mu-
tation.
To test the hypothesis that diminished PPF in both
the loss- and gain-of-function mutants could be restored
by titrating small Mafs, we first examined the abundance
of small Maf expressed in the bone marrow of mice of
each genotype by immunoblotting. The least small Maf
protein was detected in the bone marrow of mafG2/2
mutant mice, while the most abundant was in mice bear-
ing G1-HRD-MafK or MafG transgenes; wild-type and
compound mutant mice displayed intermediate levels of
small Maf accumulation (Figure 4A). When we measured
PPF in megakaryocytes recovered from mafG2/2 ::
TgMafK/GFP or TgMafG/GFP compound mutant mice, the fre-
quency was close to normal (Figure 4D; Table 2B). In
contrast, no PPF recovery was observed in control com-
pound mutant mafG2/2::TgGFP megakaryocytes (Figure
4E). Among the MafK transgenics, PPF recovery was
more efficient in lines 548 and 686, which produce MafK
at relatively higher levels (Table 2B), while, conversely,
only 50% PPF recovery was seen when line 549 (a low
level MafK producer; Table 2B) was employed. Among
the MafG transgenics, line 825, which produces MafG
at high levels, displayed the most efficient PPF restora-
tion in the mafG null mutant background (Table 2B), while
line 705, which expressed MafG at very low levels, dis-
played inefficient PPF recovery (Table 2B). These resultsFigure 4. Proplatelet Formation and Thromboxane Synthetase Ex-
demonstrate that the mafG deficiency in megakaryo-pression in Megakaryocytes of Mice Expressing Different Levels of
poiesis can be overcome by quantitative complementa-Small Maf
tion with transgene-derived small Mafs. We therefore(A) Small Maf expression levels in compound mutant mice were
examined (see Figure 3G). Two representative high level producers conclude that an optimal quantitative balance between
(TgMafK686 and TgMafG825) are shown in both wild-type and mafG2/2 the small Maf proteins and their partner molecules is
backgrounds. required for complete restoration of PPF (see below).
(B–E) Proplatelet formation was analyzed in megakaryocytes from a The data also show that MafK can complement the mafG
wild-type mouse (B), its mafG null littermate (C), a mafG2/2 ::TgMafK548
null allele, providing additional evidence that the twomouse (D), and a mafG2/2 ::TgGFP28 mouse (E). Acetylcholinesterase
activity stains dark brown (B and C), and GFP-positive megakaryo-
cytes were observed by fluorescence microscopy (D and E).
(F) Thromboxane synthetase (TXS) mRNA levels were determined
transgenic lines (548 and 549) (middle). TXS mRNA levels are fullyby real-time quantitative RT-PCR (Experimental Procedures). The
or partially restored in mafG2/2 ::TgMafK548 or mafG2/2 ::TgMafK549 com-expression levels were normalized to ribosomal RNA in the same
pound mutant mice (right). Each value represents the average ofcDNA preparation. TXS mRNA was reduced in mafG null megakaryo-
three different RNA samples, and the error bar indicates the stan-cytes compared to that in wild-type megakaryocytes (left). TXS
dard deviation.mRNA was also reduced in megakaryocytes of two different MafK
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proteins may be functionally interchangeable during presented here provides crucial insight into the question
of MARE dependence for gene regulation during eryth-megakaryopoiesis (Onodera et al. 2000). However, the
ropoiesis. Excessive MafK expression was found to le-efficiency of PPF recovery by MafK and MafG might
thally impair primitive erythropoiesis in vivo by per-differ slightly, assuming that the transgene expression
turbing transcriptional regulation mediated by MAREs.levels of the two are genuinely comparable (see Dis-
Analysis of a leucine zipper mutant of MafK, L2PM4Pcussion).
confirmed the conclusion that the embryonic anemia
was a direct effect of excess functional MafK, since theMARE-Regulated Target Gene Expression Requires
MafK L2PM4P mutant cannot dimerize with other bZipan Optimal Quantitative Balance of Small
factors nor can it bind to MARE sites.Mafs and Activating CNC Partners
One explanation for the detrimental consequence ofIf the quantitative balance of small Mafs and their het-
MafK overexpression in embryos is that unproductiveerodimeric activating CNC partner molecules deter-
MafK homodimers or heterodimers (e.g., MafK/Fos ormine transcription levels from MARE-dependent target
MafK/MafG; Kataoka et al. 1995) bind to target MAREs,genes, we would predict that we would observe dimin-
thereby obstructing binding by CNC:small Maf activat-ished target gene transcription in cells having either too
ing factors. Alternatively, MafK may sequester coactiva-little or too much small Maf protein. From previous gene
tors from MAREs by forming an anomalous heterodimertargeting analyses, p45 NF-E2 was shown to be an im-
of lower affinity for the site. The present data showedportant component of MARE binding activity, as is MafG
that the MafK L2PM4P mutant did not interact with any(Lecine et al. 1998a), and thromboxane synthase (TXS)
such putative corepressor in a functional sense, sug-was identified as a direct target gene of p45 (Deveaux
gesting that if squelching or competition for unknownet al. 1997). We found that TXS gene expression was
cofactors does play a role in MARE dependence, thereduced in both mafG null mutant as well as in MafK-
MafK bZip structure is necessary for productive interac-overexpressing transgenic megakaryocytes (Figure 4F),
tion (Nagai et al., 1998).indicating that small Mafs are obligate partners of p45
While MafK overexpression resulted in diminishedin megakaryocytes and thus act on the same cellular
blood cell number in transgenic embryos, the erythroidtarget genes. When we analyzed megakaryocytes from
cells were hemoglobinized and their morphology ap-mafG2/2 ::TgMafK/GFP compound mutants, we found that
peared to be normal, in stark contrast to the direct ef-TXS mRNA was restored to normal levels (Figure 4F) in
fects on erythropoiesis encountered in the progenitorsparallel with recovery of PPF. In summary, these results
of GATA-1 “knock-down” mutant embryos (Takahashishow that either positive or negative perturbation of
et al., 1997) or alas-e null mutant embryos (Nakajima etsmall Maf protein levels from the cellular norm lowers
al., 1999). Since the G1-HRD cassette is active duringtranscription from MARE-regulated target genes, and
erythroid progenitor stages (N. Suwabe and M. Y., un-that maximal transcriptional activity is attained by bal-
published data), our results suggest that while progeni-anced intracellular small Maf and CNC concentrations.
tor proliferation may be somewhat compromised in
MafK transgenic embryos, terminal differentiation ofDiscussion
committed erythroid cells is not strongly affected. In
support of this contention, several prior observations
The number of cellular proteins that can mediate various
suggested that overexpression of MafK might lead to
aspects of transcriptional regulation via Maf recognition premature erythroid differentiation, resulting in dimin-
elements (MAREs) is both large and complex. Transcrip- ished blood cell number. For example, conditional over-
tion factors include members of the AP1 family (Jun and expression of MafK induced premature differentiation
Fos and their relatives), six CNC, and three small as of murine erythroleukemia cells in culture (Igarashi et
well as three large Maf proteins, thus bringing the total al., 1995b). Thus, increased MafK levels might trigger
number of factors that can potentially interact to influ- premature differentiation in erythroid progenitor cells
ence transcriptional responses through MAREs to more that are already poised to differentiate. In accord with
than fifteen. However, germ line mutation of genes en- this hypothesis, we recently demonstrated that the ex-
coding various MARE binding proteins have previously pression of mafK in the erythroid lineage is directly regu-
failed to demonstrate cell autonomous erythroid pheno- lated by GATA-1 (Katsuoka et al., 2000). Thus in the
types, despite overwhelming evidence that the MARE present context, MafK expression directed by GATA-1
sequence is vital to erythroid development (Shivdasani regulatory sequences should initiate earlier than does
et al. 1995; Kotkow and Orkin 1996; Farmer et al. 1997; endogenous mafK expression in erythroid progenitors.
Itoh et al. 1997; Kuroha et al. 1998; Shavit et al. 1998). If erythroid progenitors begin to differentiate when the
The only exception to this conclusion was provided from MafK transgene is transcribed, then this may cue preco-
studies of the mafK::mafG compound mutant mouse, cious erythroid differentiation and thus indirectly pro-
which displayed erythroid membrane abnormalities hibit adequate proliferation and expansion of the pro-
(Onodera et al., 2000). However, erythropoiesis in this genitor pool.
compound mutant was deemed normal as judged by Unlike its effect on erythropoiesis, megakaryopoiesis
the production of globins and heme biosynthetic en- was affected by even low MafK transgene levels, re-
zymes and the presence of enucleated definitive red sulting in striking PPF inhibition. This suggests that at
blood cells. These observations raised the question of least one stage of megakaryopoiesis is much more sen-
whether or not MARE-dependent transcription was ac- sitive to alterations in small Maf protein concentration
tually indispensable for erythropoiesis. than any step in erythropoiesis. Consistent with this
notion, only a megakaryocytic phenotype was observedThe analysis of MafK transgenic overexpression mice
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lated with PPF frequency, which directly supported the
contention that Maf target genes are negatively affected
by either a deficit or a surplus of small Maf protein. The
relationship between PPF frequencies and the abun-
dance of small Mafs is illustrated diagrammatically in
Figure 5. Since the major small Maf protein in adult
megakaryocytes is MafG (Lecine et al., 1998b; Shavit et
al., 1998), it would follow that mafG null megakaryocytes
would display most markedly diminished PPF fre-
quency. Transgenic MafK or MafG expression paralleled
both the degree of PPF inhibition as well as the PPF
rescue potential in mafG null megakaryocytes.
Close inspection of the data could suggest a differ-
ence between MafK and MafG in their ability to comple-
ment PPF deficiencies. Since the anti-small Maf antise-
rum reacts approximately twice as strongly to MafK as
to MafG (Experimental Procedures), we calculate that
the abundance of MafK derived from TgMafK686 and MafGFigure 5. In Vivo Titration of Small Maf Activity Is Required for Maxi-
mum PPF from TgMafG825 are almost the same (Figure 4A). Nonethe-
When small Maf proteins are low, such as in mafG null mutant less, TgMafG825 showed complete PPF recovery, while
megakaryocytes, PPF frequency is also low. In small Maf surplus, TgMafK686 only partially rescued (Table 2B). The data there-
such as in megakaryocytes from MafK or MafG-overexpressing fore suggest that MafK might be less efficient for PPF
transgenic mice, PPF is also low. PPF is recovered in megakaryo- than MafG. However, any conclusion regarding func-
cytes from mafG2/2 ::TgMafK/GFP or TgMafG/GFP compound mutant mice
tional differences between MafK and MafG will requireaccording to the expression level of the transgene.
more precise quantification of the endogenous and
transgenic expression levels of the small Maf proteins
as well as development of an assay with less intrinsicin either the p45 or small maf gene disruption experi-
variability than PPF scores (e.g., see Tables 2A and 2B:ments. Thus, the different sensitivity to fluctuations in
PPF among wild-type mice, or among all mafG2/2 mice).small Maf concentrations may be related to the com-
When the abundance of small Maf proteins was exam-plexity of bZip factor composition in erythroid cells ver-
ined using an anti-small Maf antiserum that reacts withsus the relative simplicity in the megakaryocytic milieu.
both MafK and MafG, we found that the overall small MafMARE binding activity detected in nuclear extracts from
factor concentration in the highest producer transgenicprimary megakaryocytes consisted solely of p45:MafG
line increased by (at most) only 2-fold over the endoge-heterodimers (Lecine et al., 1998b). In contrast, nuclear
nous level (see Figures 3G and 4A). This indicates thatextracts prepared from fetal liver, representing primarily
small Maf factors can serve as a very sensitive switcherythroid cells, contained multiple MARE binding activi-
of MARE-dependent gene regulation, since only a 2-foldties, among them p45-small Maf heterodimers (Lecine
increase in total small Maf concentration dramaticallyet al., 1998b). Thus, in erythroid cells, the number of
affects both the composition of MARE binding com-contributing proteins to the bZip network is much more
plexes detectable by EGMSA and the transcription ofdiverse than in megakaryocytes. Based on these obser-
MARE-dependent genes.vations, we propose that it may be easier to compensate
Germ line mutations in both the small maf and CNCfor the loss of any one member of this interactive net-
family genes has helped to unravel the intricacy of thiswork of factors within the erythroid environment. There-
CNC:small Maf:AP1 bZip network in various biologicalfore, any effects of a small MafK excess generated from
contexts, such as erythroid membrane protein regula-a low level producer transgenic line may be masked or
tion, maintenance of neurological function (Onodera etmuted in erythroid cells. In contrast, the wild-type MARE
al., 2000), and defense mechanisms against oxidativebinding constituents present in megakaryocytes appear
stress (Itoh et al., 1997). Thus, the small Maf factors actto consist of only p45, MafG, and (to a lesser extent)
in these processes as vital effectors that positively andMafK. This may well explain the fact that megakaryo-
negatively regulate the activity of MARE-dependentcytes are more sensitive to subtle alterations in small
transcriptional processes essential for cellular function.Maf abundance. Thus, PPF appears to serve as a very
sensitive bellwether of small fluctuations in this bZip
Experimental Proceduresnetwork.
We previously proposed that small Maf factors serve
Transgenes and Transgenic Mice
as a finely balanced molecular switch for turning on and To construct the G1-HRD-MafK, pIM-MafK was first generated by
off MARE-dependent transcription (Igarashi et al., 1994). replacing lacZ gene of pIM-lacZ (NotI-NotI fragment; Motohashi et
al., 1996) with MafK cDNA (SmaI-PstI fragment; Igarashi et al.,However, conclusive evidence supporting that model
1995a). The KpnI-StuI fragment of pIM-MafK was then replaced withawaited development of a robust and sensitive assay
a KpnI-NotI fragment from IE3.9int-lacZ (Onodera et al., 1997) toto analyze small Maf function in vivo. Using PPF as the
generate G1-HRD-MafK. MafK L2PM4P was generated from MafKassay, we demonstrated the in vivo relevance of the
by introducing three amino acid mutations in the leucine zipper
quantitative balance between small Maf factors and their using PCR. The original leucine zipper motif (LERQRVELQQEV
heterodimeric partner molecules. MARE-dependent EKLARENSSMRLELDALRSKYEAL; aa 79 to 114) was mutated to
LERQRVEPQQEVEKLARENSSPKLELDALRSKYEAL. MafG cDNATXS gene expression levels in megakaryocytes corre-
Cell
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was obtained by RT-PCR and cloned into pGEM-T (Promega). G1- lated to express approximately the same amounts of their respective
transgenic protein products (1/2 20%).HRD-MafK-L2PM4P and G1-HRD-MafG were constructed using a
similar strategy. Transgenic mice were generated as previously de-
scribed (Motohashi et al., 1996). G1-HRD-MafK, G1-HRD-MafK Immunoblotting
L2PM4P and G1-HRD-MafG transgenic mice were identified using Nuclear extracts were prepared from the bone marrow cells of adult
the common upstream primer; 59-TGTCTCACAACCCTTTCTGTCC-39. mice (between 1 month and 8 months old) of each transgenic line
The downstream primers are 59-CTTGGAGCGCAGGGCATCTA-39, (Dignam, 1990), and 15 mg of nuclear extract was applied per lane.
59-GCGGCTGAGAAGGGTACAGA-39, and 59-TCAAAGACCTGCCT MafK expression level was examined by anti-p18 antibody (Santa
GGCAAC-39, respectively. In transgenic lines bearing G1-HRD-MafK Cruz; Motohashi et al., 1996). Total small Maf expression level was
or -MafG, G1-HRD-GFP (Takahashi et al., 2000) was coinjected. determined using an anti-small Maf antiserum (Igarashi et al.,
To analyze mafG2/2 ::TgMafK/GFP or TgMafG/GFP mice, heterozygous or 1995b). Autoradiographs were scanned using Photoshop 4, and the
homozygous mafG mutant mice were intercrossed with G1-HRD- band intensities were quantified using the NIH-Image program.
MafK or -MafG/GFP transgenic mice. mafG1/-::TgMafK/GFP or
TgMafG/GFP mice were then bred with mafG1/- mice, and the resultant Real Time Quantitative RT-PCR
litters were used for the experimental analysis. mafG mutant and Expression of TXS mRNA was detected by real time quantitative
wild-type alleles were determined by PCR (Onodera et al., 2000). RT-PCR analysis (ABI PRISM 7700 Sequence Detection System).
Primers used were: 59-GCATCCAGGGACGC-39 and 59-AGGCCA
Histology CACTGGCC-39. The TaqMan fluorescent probe was: 59-Fam-
Transgenic founder embryos were analyzed at E10.5. Embryos were TTCAACATCCAGAGGTGTTACTGCTGT-Tamra-39.
fixed in 3.7% formaldehyde at room temperature for 2 hr, and frozen
sections were prepared using a cryostat. For immunohistochemis- Proplatelet Formation (PPF) Assay
try, anti-hemoglobin antibody (ICN Pharmaceuticals, Inc.) was used Megakaryocytes were isolated from the bone marrow of four- to
at 1:50 dilution followed by application of horseradish peroxidase- ten-month-old mice, and projection of proplatelets was observed
conjugated anti-rabbit IgG at 1:200 dilution. Diaminobenzidine was as described (Onodera et al., 2000). In the lines bearing TgGFP,
used as chromogen, and methyl green was used as counterstain. TgMafK/GFP, or TgMafG/GFP, only GFP-positive cells were scored.
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